AU2018215809B2 - N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 H-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as CK1 and/or IRAKI inhibitors for treating cancer - Google Patents

N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 H-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as CK1 and/or IRAKI inhibitors for treating cancer Download PDF

Info

Publication number
AU2018215809B2
AU2018215809B2 AU2018215809A AU2018215809A AU2018215809B2 AU 2018215809 B2 AU2018215809 B2 AU 2018215809B2 AU 2018215809 A AU2018215809 A AU 2018215809A AU 2018215809 A AU2018215809 A AU 2018215809A AU 2018215809 B2 AU2018215809 B2 AU 2018215809B2
Authority
AU
Australia
Prior art keywords
straight
branched
alkyl
halide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018215809A
Other languages
English (en)
Other versions
AU2018215809A1 (en
Inventor
Yinon Ben-Neriah
Dansu Li
Irit SNIR-ALKALAY
Joseph Vacca
Avanthika VENKATAC-IALAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2018215809A1 publication Critical patent/AU2018215809A1/en
Application granted granted Critical
Publication of AU2018215809B2 publication Critical patent/AU2018215809B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018215809A 2017-02-01 2018-01-30 N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 H-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as CK1 and/or IRAKI inhibitors for treating cancer Ceased AU2018215809B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762453192P 2017-02-01 2017-02-01
US62/453,192 2017-02-01
PCT/IL2018/050100 WO2018142393A1 (en) 2017-02-01 2018-01-30 N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
AU2018215809A1 AU2018215809A1 (en) 2019-08-15
AU2018215809B2 true AU2018215809B2 (en) 2021-12-23

Family

ID=61198874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018215809A Ceased AU2018215809B2 (en) 2017-02-01 2018-01-30 N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 H-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as CK1 and/or IRAKI inhibitors for treating cancer

Country Status (15)

Country Link
US (2) US11072599B2 (enExample)
EP (1) EP3577108B1 (enExample)
JP (1) JP7142646B2 (enExample)
KR (1) KR20190115017A (enExample)
CN (1) CN110475771B (enExample)
AU (1) AU2018215809B2 (enExample)
CA (1) CA3052247A1 (enExample)
ES (1) ES2902885T3 (enExample)
IL (1) IL268128B2 (enExample)
MX (1) MX394556B (enExample)
NZ (1) NZ755447A (enExample)
RU (1) RU2761457C2 (enExample)
SG (1) SG11201906681PA (enExample)
TW (1) TW201837027A (enExample)
WO (1) WO2018142393A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62728B1 (sr) * 2015-08-04 2022-01-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivat pirazol pirimidina i njegove upotrebe
KR20200130287A (ko) * 2018-02-08 2020-11-18 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도
CN114127058B (zh) * 2019-07-04 2024-06-25 深圳国顺康医药科技有限公司 一种杂环化合物、其药物组合物及用途
KR20230069169A (ko) * 2020-09-17 2023-05-18 얀센 파마슈티카 엔.브이. 카제인 키나제 1 델타 조절제
WO2022232259A1 (en) * 2021-04-28 2022-11-03 Cornell University Soluble adenylyl cyclase (sac) inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081679A1 (en) * 2014-11-20 2016-05-26 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
WO2016149756A1 (en) * 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
WO2017021969A1 (en) * 2015-08-04 2017-02-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pyrazole pyrimidine derivative and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
BR112014010563B1 (pt) 2011-11-04 2021-01-12 Jasco Pharmaceuticals, LLC compostos inibidores da aminopirimidina quinase
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AU2014337044A1 (en) * 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081679A1 (en) * 2014-11-20 2016-05-26 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
WO2016149756A1 (en) * 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
WO2017021969A1 (en) * 2015-08-04 2017-02-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pyrazole pyrimidine derivative and uses thereof

Also Published As

Publication number Publication date
US20220017493A1 (en) 2022-01-20
EP3577108A1 (en) 2019-12-11
IL268128A (en) 2019-09-26
US20200354340A1 (en) 2020-11-12
JP7142646B2 (ja) 2022-09-27
US11072599B2 (en) 2021-07-27
RU2019127038A3 (enExample) 2021-03-17
CN110475771A (zh) 2019-11-19
US11999721B2 (en) 2024-06-04
MX394556B (es) 2025-03-24
WO2018142393A1 (en) 2018-08-09
NZ755447A (en) 2023-05-26
AU2018215809A1 (en) 2019-08-15
IL268128B (en) 2022-11-01
TW201837027A (zh) 2018-10-16
CN110475771B (zh) 2022-09-02
ES2902885T3 (es) 2022-03-30
MX2019009083A (es) 2019-09-10
RU2761457C2 (ru) 2021-12-08
IL268128B2 (en) 2023-03-01
SG11201906681PA (en) 2019-08-27
JP2020505468A (ja) 2020-02-20
RU2019127038A (ru) 2021-03-02
ES2902885T8 (es) 2022-04-06
EP3577108B1 (en) 2021-10-20
KR20190115017A (ko) 2019-10-10
CA3052247A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
US12514859B2 (en) Pyrazole pyrimidine derivative and uses thereof
US11958855B2 (en) Aurora kinase inhibitors for inhibiting mitotic progression
US11999721B2 (en) Pyrazole compounds and uses thereof
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
HK40019133B (en) N1-(4-(5-(cyclopropylmethyl)-1-methyl-1h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer
HK1256535B (en) Pyrazole pyrimidine derivative and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired